Next Article in Journal
Conventional and Virtual Reality Mirror Therapies in Upper Obstetric Brachial Palsy: A Randomized Pilot Study
Next Article in Special Issue
Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Previous Article in Journal
Hyperthyroidism Is Associated with the Development of Vasospastic Angina, but Not with Cardiovascular Outcomes
Previous Article in Special Issue
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
Open AccessReview

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma

1
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
2
Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, Italy
3
Department of Hematology I, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(9), 3022; https://doi.org/10.3390/jcm9093022
Received: 14 August 2020 / Revised: 13 September 2020 / Accepted: 15 September 2020 / Published: 19 September 2020
(This article belongs to the Special Issue New Therapies and Therapeutic Approaches in Multiple Myeloma)
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is universally expressed by normal and neoplastic plasma cells and plays a critical role in the proliferation, survival and tumor progression in multiple myeloma (MM). B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) have been recognized as proliferation ligands for BCMA in the bone marrow microenvironment. Soluble BCMA levels in the serum correlates with disease phase and tumor burden and is a predictor of progression-free survival (PFS) and overall survival (OS). Recently, the introduction of new monoclonal antibodies against CD38 (Daratumumab and Isatuximab) and SLAM7 (Elotuzumab) has changed the therapeutic approach to MM, improving the response rate and the time to progression, both in newly diagnosed and refractory/relapsed patients. Among the surface antigens on MM cells, BCMA is a suitable target for the design of new antibody-based strategies. Experimental approaches targeting BCMA are currently being investigated and include antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs) and genetically engineered T-cells with chimeric antigen receptors (CAR). In this review we summarize the more recent findings about BCMA biologic rationale as a therapeutic target and report the updated results of preclinical and clinical studies focused on ADCs and bsAbs targeting BCMA. View Full-Text
Keywords: multiple myeloma; B-cell maturation antigen; monoclonal antibody treatment multiple myeloma; B-cell maturation antigen; monoclonal antibody treatment
Show Figures

Figure 1

MDPI and ACS Style

Dalla Palma, B.; Marchica, V.; Catarozzo, M.T.; Giuliani, N.; Accardi, F. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. J. Clin. Med. 2020, 9, 3022.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop